SpyGlass Pharma's BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial

SpyGlass Pharma has reported 4-year interim results from the first-in-human (FIH) trial of its Bimatoprost Drug Pad-IOL System (BIM-IOL System), extending what the company describes as the “longest durability record to date for a sustained drug delivery implant in glaucoma.”¹ The investigational system pairs a monofocal intraocular lens (IOL) with non-bioerodible, bimatoprost-eluting drug pads and is implanted during routine cataract surgery in patients with mild-to-moderate open-angle glaucoma (OAG) or ocular hypertension (OHT).

The 48-month readout adds a further year of follow-up to data Ophthalmology Times covered at the 36-month mark in November 2025,² and it arrives as the company's 2 registrational phase 3 trials continue to enroll.³

Four-year results

The FIH study is a single-center, prospective trial in which 23 patients were sequentially assigned 1:1:1 to 3 dose groups of 75 mcg, 150 mcg, and 300 mcg. The version of the device used in this study was designed to deliver bimatoprost for up to 7 years, and SpyGlass designed the trial to follow patients for 7 years.¹

Among the 21 evaluable patients at 48 months, mean IOP across the 3 dose groups fell from 25.1 ± 2.5 mmHg at baseline, measured after washout of prior medications, to 15.9 ± 2.8 mmHg, a 37% reduction. Eighteen of the 21 patients (86%) remained off all topical IOP-lowering drops, and 90% maintained best-corrected distance visual acuity (BCDVA) of 20/25 or better. The company reported no product-related adverse events.¹

Two patients left the study before the 36-month visit: 1 relocated outside the country, and 1 was discontinued after a cancer diagnosis.¹

Paul Yoo, OD, senior vice president of clinical development at SpyGlass, said that 4 years of sustained IOP reduction, with daily drops largely eliminated and safety and visual outcomes preserved, sets "a new benchmark for durable, drop-free disease control." He added that the company expects to gather further long-term safety and efficacy evidence as it follows patients through 2029.¹

Chief executive officer Patrick Mooney characterized the readout as the first time a sustained-release glaucoma implant has shown durable safety and efficacy over 4 years. He pointed to roughly 1 million cataract procedures performed each year in the United States in patients who also have glaucoma, and said the system is designed to slot into a standard cataract workflow, addressing both lens opacity and elevated IOP in a single procedure.¹

Reading the trajectory

Set against earlier timepoints from the same cohort, the 4-year figures show IOP control holding steady while the drop-free rate has drifted modestly downward.

At 18 months, results presented at the 2025 ASCRS annual meeting showed mean IOP falling from 25.1 mmHg to 14.1 mmHg, with all patients off topical IOP-lowering medications.⁴ By 36 months, SpyGlass reported a 37% mean IOP reduction across dose groups, with 95% of patients off all topical drops.⁵ At 48 months, the percentage reduction is unchanged at 37%, but the proportion of drop-free patients has slipped to 86%, and mean IOP sits at 15.9 mmHg.

The release does not say which dose groups the 3 patients back on topical therapy belonged to, when they restarted drops, or whether any additional glaucoma intervention was required.

The study's design also warrants context. With 21 evaluable patients at a single site, no control arm, and outcomes pooled across 3 doses, the FIH trial is a durability signal rather than a comparative efficacy result. Mooney has acknowledged as much, telling a regional business publication earlier this year that a key challenge of the 3-year dataset was that it "was single-site and not controlled."⁶

Controlled data and the path to approval

That gap is what the company's later studies are designed to close. In March, SpyGlass reported 12-month results from its multicenter phase 1/2 trial, in which 104 patients were randomized 2:1:1 to a 78 mcg BIM-IOL System, a 39 mcg BIM-IOL System, or a standard monofocal IOL with twice-daily timolol.⁷ Mean IOP fell 34% and 42% in the 2 BIM-IOL groups, compared with 35% in the timolol arm, and 97% of BIM-IOL patients were off all topical IOP-lowering therapy at 1 year.⁷

In January, SpyGlass randomized the first patients in SGP-005 and SGP-006, its 2 registrational phase 3 trials of the system in patients with OAG or OHT.³ The device in those trials is designed to deliver bimatoprost consistently for 3 years, a shorter target than the up-to-7-year design in the FIH cohort.¹ The company continues long-term follow-up in both the FIH and phase 1/2 studies and plans to pursue a 505(b)(2) New Drug Application with the FDA.¹

SpyGlass has also moved to secure its supply chain ahead of potential commercialization. On October 1, the company acquired Advanced Vision Science, the Santen subsidiary that manufactures the IOL used in both phase 3 trials, for approximately $13 million in cash.⁸

Where it fits in interventional glaucoma

The BIM-IOL System enters a field already reshaped by procedural pharmaceuticals. Intracameral options such as Durysta (bimatoprost implant; AbbVie) and iDose TR (travoprost intracameral implant; Glaukos) have given glaucoma specialists ways to reduce dependence on daily drops, a shift that panelists in a recent Ophthalmology Times clinical forum tied to the broader move toward earlier, more proactive interventional care.⁹

SpyGlass is positioning its system differently. Rather than requiring a separate procedure or a glaucoma subspecialist, the drug pads ride on the IOL itself, sitting at the optic–haptic junction outside the visual axis. The company has argued that this opens IOP management to the large share of cataract surgeons who do not routinely perform MIGS; it has cited data indicating that only about one-third of surgeons perform MIGS at least twice a month.³

Whether that pitch holds will depend on phase 3. The registrational trials will need to show that the 3-year device delivers comparable IOP control against an active comparator in a randomized, masked setting, and the FIH cohort will need to show what happens as drug release tapers and patients age. For now, the 4-year data offer the clearest evidence yet that an IOL-mounted reservoir can keep a small group of patients largely free of drops well beyond the typical duration of currently approved sustained-release implants.

The SpyGlass platform was developed at the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine, and the company was founded in 2019 by Malik Y. Kahook, MD, and Glenn Sussman.¹

References

1. SpyGlass Pharma announces positive 4-year data from first-in-human trial of its innovative BIM-IOL System. News release. SpyGlass Pharma. October 19, 2026. Accessed October 19, 2026. https://ir.spyglasspharma.com/news-releases/news-release-details/spyglass-pharma-announces-positive-4-year-data-first-human-trial

2. SpyGlass Pharma releases positive data from 2 trials of Bimatoprost Drug Pad-IOL System. Ophthalmology Times. November 10, 2025. Accessed October 19, 2026. https://www.ophthalmologytimes.com/view/spyglass-pharma-releases-positive-data-from-2-trials-of-bimatoprost-drug-pad-iol-system

3. SpyGlass Pharma randomizes first patients in 2 phase 3 clinical trials of the BIM-IOL System. Ophthalmology Times. January 20, 2026. Accessed October 19, 2026. https://www.ophthalmologytimes.com/view/spyglass-pharma-randomizes-first-patients-in-2-phase-3-clinical-trials-of-the-bim-iol-system

4. SpyGlass reports data. Ophthalmology Management. 2025. Accessed October 19, 2026. https://ophthalmologymanagement.com/news/2025/spyglass-reports-data/

5. SpyGlass Pharma reports fourth quarter and full year 2025 earnings and provides a corporate update. News release. SpyGlass Pharma. March 26, 2026. Accessed October 19, 2026. https://www.barchart.com/story/news/990775/spyglass-pharma-reports-fourth-quarter-and-full-year-2025-earnings-and-provides-a-corporate-update

6. SpyGlass valued at $900M after IPO. Orange County Business Journal. 2026. Accessed October 19, 2026. https://www.ocbj.com/oc-homepage/spyglass-valued-at-900m-after-ipo/

7. SpyGlass Pharma reports positive 12-month phase I/II results for BIM-IOL System in glaucoma and ocular hypertension. Ophthalmology Times. March 11, 2026. Accessed October 19, 2026. https://www.ophthalmologytimes.com/view/spyglass-pharma-reports-positive-12-month-phase-i-ii-results-for-bim-iol-system-in-glaucoma-and-ocular-hypertension

8. SpyGlass Pharma acquires Advanced Vision Science, Inc. (AVS), securing scalable commercial IOL supply and accelerating lens portfolio expansion capability. Exhibit 99.1, Form 8-K. SpyGlass Pharma. October 1, 2026. Accessed October 19, 2026. https://www.sec.gov/Archives/edgar/data/0001778922/000177892226000049/exhibit991-8kprx100126.htm

9. Transforming glaucoma management: interventional strategies and sustained drug delivery. Ophthalmology Times Clinical Forum. Accessed October 19, 2026. https://www.ophthalmologytimes.com/clinical-forums/transforming-glaucoma-management-interventional-strategies-and-sustained-drug-delivery